• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

• 药品评价-临床研究 •    下一篇

肾康注射液治疗糖尿病肾病和慢性肾功能衰竭系统评价再评价及成本效果分析

郜文   

  1. 北京医药卫生经济研究会
  • 收稿日期:2018-09-14 修回日期:2018-09-14 出版日期:2018-08-25 发布日期:2018-08-25

Shen Kang Injection in the Treatment of Diabetic Nephropathy or Chronic Renal Failure: An Overview of Systematic Reviews and Cost-effectiveness Analysis

GAO Wen   

  1. Medical and Health Economic Research Association
  • Received:2018-09-14 Revised:2018-09-14 Online:2018-08-25 Published:2018-08-25

摘要: 【】 目的:对肾康注射液治疗糖尿病肾病和慢性肾功能衰竭的疗效系统评价进行再评价,同时对其治疗的成本效果进行分析。方法:计算机检索中国知网、万方数据库、维普、中国生物医学文献数据库、PubMed、Embase和The Cochrane Library数据库,搜集肾康注射液治疗糖尿病肾病和慢性肾功能衰竭的系统评价,检索时限均为建库至 2018年6月18日。由2位研究者独立进行文献筛选、资料提取并采用AMSTAR工具评价纳入研究的方法学质量。采用成本效果分析比较肾康注射液联合常规治疗与单纯常规治疗慢性肾功能衰竭的经济性。结果:最终纳入8篇系统评价,纳入的系统评价质量尚可,条目1“是否提供了前期设计方案” 均未报告。系统评价再评价结果显示:与常规治疗相比,在常规治疗基础上联合肾康注射液或肾康注射液联合前列地尔可提高(早起)糖尿病肾病以及慢性肾功能衰竭的治疗效果。在成本效果分析方面,与单纯常规治疗相比,治疗周期为2周时,肾康注射液联合常规治疗可更多的降低慢性肾衰竭患者血清肌酐(Scr)、尿素氮(BUN);治疗周期大于等于4周时,肾康注射液联合常规治疗可更多的降低慢性肾衰竭患者血清肌酐、尿素氮,增加肾小球滤过率(GFR),多支付相应成本。结论:与单纯常规治疗相比,肾康注射液联合常规治疗的成本略高,效果更好。

Abstract: 【】 Objective:To assess the efficacy of Shen Kang injection in the treatment of diabetic nephropathy or chronic renal failure by overview the systematic reviews, at the same time, to analysis cost-effectiveness of the Shen Kang injection in the treatment of diabetic nephropathy or chronic renal failure. Methods:We electronically searched databases including CNKI, WanFang Data, VIP, CBM, PubMed, Embase and The Cochrane Library to collect systematic reviews or Meta-analyses about Shen Kang injection for diabetic nephropathy or chronic renal failure from inception to June 18, 2018.Two reviewers independently screened literatures, extracted data, and then AMSTAR tool was used to assess the methodological quality of included studies. Meanwhile, the cost-effectiveness analysis was used to compare the economic exhaustion of Shen Kang injection combined with conventional treatment and conventional treatment. Results:A total of 8 systematic reviews/Meta-analyses were included. The quality of systematic reviews/Meta-analyses were good, the item 1 of “Was an ‘a priori’ design provided” was not reported in the 8 systematic reviews/Meta-analyses. The results of overview showed that: compared with the conventional treatment, the conventional treatment combined Shen Kang injection or the conventional treatment combined Shen Kang injection combined alprostadil could improve the clinical efficacy in the treatment of diabetic nephropathy or chronic renal failure.as for cost-effectiveness, compared with conventional treatment, the treatment period was 2 weeks, Shen Kang Injection combined with conventional treatment can reduce the serum creatinine (Scr) and the usea nitrogen (BUN); the treatment period was 4 weeks or longer, Shen Kang Injection combined with conventional treatment can reduce the serum creatinine and the urea nitrogen in patients with CRF, increased glomerular filtration rate (GFR), and need to pay the corresponding cost. Conclusion: compared with the conventional treatment, the clinical efficacy of combination with Shen Kang Injection and conventional treatment is slightly higher, but the effect is better.